Lithium Linked to Risk for Thyroid Dysfunction, CKD in Bipolar Disorder
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Feb. 12, 2025 -- Lithium is associated with an increased risk for thyroid dysfunction and chronic kidney disease (CKD) in patients with incident bipolar disorder (BD), according to a study published online Feb. 11 in JAMA Network Open.
Joe Kwun Nam Chan, Ph.D., from the University of Hong Kong, and colleagues examined the risk for thyroid and kidney dysfunction in patients aged 15 years or older with incident BD treated with lithium and other mood stabilizers and antipsychotics in an Asian population in Hong Kong.
Overall, 4,752, 4,500, and 7,029 individuals had analyzable data for hypothyroidism, hyperthyroidism, and CKD, respectively. The researchers found that compared with nonlithium treatments, lithium was associated with an increased risk for hypothyroidism and CKD3+ (adjusted hazard ratios, 2.00 and 1.35, respectively), but not with CKD4+ or end-stage kidney disease. Elevated rates of hypothyroidism, hyperthyroidism, and CKD3+ were seen in association with higher lithium serum levels (adjusted hazard ratios, 2.08, 1.81, and 2.11, respectively). There was an association seen for a greater number of lithium toxicity episodes with increased CKD3+ risk. Compared with lithium, valproate, olanzapine, quetiapine, and risperidone generally exhibited a lower likelihood of thyroid dysfunction and CKD3+, with no difference in advanced CKD. Mean lithium serum levels >0.5028, >0.5034, and >0.5865 mEq/L represented thresholds associated with hypothyroidism, hyperthyroidism, and CKD3+, respectively.
"Our findings further identified thresholds of lithium serum levels associated with thyroid and kidney abnormalities, thereby providing empirical evidence to inform clinical guidelines on recommending lithium treatment that balances the efficacy and safety," the authors write.
Several authors disclosed ties to the pharmaceutical and medical technology industries.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted February 2025
Read this next
Age-, Sex-, Race-Specific Standards for Thyroid Diseases May Reclassify Many Patients
WEDNESDAY, May 14, 2025 -- Age-, sex-, and race-specific reference intervals for thyroid diseases reclassify many participants with subclinical hypothyroidism or hyperthyroidism...
Obinutuzumab Efficacious for Renal Response in Lupus Nephritis
WEDNESDAY, Feb. 26, 2025 -- For patients with active lupus nephritis, obinutuzumab, a humanized type II anti-CD20 monoclonal antibody plus standard therapy is more efficacious for...
Screen Time Tied to Manic Symptoms in Preteens
MONDAY, Feb. 24, 2025 -- Screen time such as social media and video games may be associated prospectively with manic symptoms in early adolescence, according to a study published...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.